NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical evidence demonstrates that CML patients with favorable responses to imatinib exhibit elevated levels of CD3-CD56+ NK cells (p = 0.0043), CD16+ NK cells (p = 0.0046) and CD57+ NK cells (p = 0.0208) (192).